Arecor Therapeutics (LON:AREC) Announces Quarterly Earnings Results

Arecor Therapeutics (LON:AREC) released its quarterly earnings data on Monday. The company reported GBX 2 earnings per share for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a negative net margin of 160.13% and a negative return on equity of 197.54%. The firm had revenue of GBX 171 million for the quarter.

Arecor Therapeutics Stock Performance

AREC opened at GBX 62 on Wednesday. The company has a current ratio of 2.05, a quick ratio of 6.24 and a debt-to-equity ratio of 6.06. The company’s fifty day moving average price is GBX 71.09 and its two-hundred day moving average price is GBX 76.02. Arecor Therapeutics has a 1-year low of GBX 35.40 and a 1-year high of GBX 100. The company has a market cap of £23.41 million, a price-to-earnings ratio of -2.70 and a beta of -0.18.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.